Human NTB-A/SLAMF6 APC-conjugated Antibody
Human NTB-A/SLAMF6 APC-conjugated Antibody Summary
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of NTB‑A/SLAMF6 in Human Blood Lymphocytes by Flow Cytometry. Human peripheral blood lymphocytes were stained with Mouse Anti-Human NTB-A/SLAMF6 APC-conjugated Monoclonal Antibody (Catalog # FAB19081A, filled histogram) or isotype control antibody (Catalog # IC003A, open histogram). View our protocol for Staining Membrane-associated Proteins.
View Larger
Detection of Human NTB-A/SLAMF6/CD352 by Flow Cytometry Functional activity of Rev1-Vpu expressed from pCG expression plasmids.(A) CMV-IE promoter-based pCG expression vectors containing vpu (left panel) or the rev1-vpu fusion gene (right panel). An enhanced version of the green fluorescent protein (eGFP) is co-expressed via an IRES. (B) Expression of Rev1-Vpu and Vpu in HEK293T cells transfected with the indicated pCG vectors. A Vpu-specific antiserum was used for detection. eGFP was detected to check transfection efficiencies. (C-F) FACS analysis of (C) CD4, (D) tetherin, (E) CD1d or (F) NTB-A receptor modulation by ZM247 Vpu and Rev1-Vpu. HEK293T cells were transfected with expression vectors for the respective surface receptor and Vpu or Rev1-Vpu. 40 h post transfection, surface receptor levels were monitored by two-color flow cytometry. Dot plots indicating the gating strategy are shown in the right panels. Bar diagrams summarizing three to five independent experiments +/- SD are shown on the left (***p<0.001; **p<0.01; *p<0.05; n.s. not significant). Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0142118), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
Background: NTB-A/SLAMF6
NTB-A (NK-T-B-antigen), also known as Ly108 and SLAMF6, is a 60 kDa type I transmembrane glycoprotein that belongs to the SLAM subgroup of the CD2 family (1). Mature human NTB-A contains a 205 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set and one Ig-like C2-set domain. It also contains a 21 aa transmembrane segment and an 84 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs (ITSMs) (2, 3). An alternately spliced isoform is truncated in the cytoplasmic domain and lacks the two ITSMs. Within the ECD, human NTB-A shares 48% aa sequence identity with mouse and rat NTB-A. The ECD of human NTB-A shares 19%‑34% aa sequence identity with comparable regions of human 2B4, BLAME, CD2F-10, CD84, CD229, CRACC, and SLAM. NTB-A is expressed on the surface of NK, T, and B lymphocytes as well as eosinophils (2, 4, 5). It interacts homophilically through weak associations between the Ig-V domains (2, 5‑7). NTB-A functions as an activating coreceptor on NK and T cells (2, 5, 6, 8). Tyrosine phosphorylation in the membrane proximal ITSM enables specific association with EAT-2, an interaction that is required for NTB-A mediated cytotoxicity of NK cells (9). Phosphorylation-dependent NTB-A association with SAP is required for full production of IFN-gamma by NK cells (5, 9). This interaction is independent of EAT-2 binding and appears to involve the membrane distal ITSM (5, 9). NTB-A deficient mice show weakened Th2 responses and elevated levels of neutrophil-derived inflammatory mediators (10). On B cells, NTB-A modulates immunoglobulin class switching and the balance between tolerance and autoimmunity (5, 11).
- Veillette, A. (2006) Immunol. Rev. 214:22.
- Bottino, C. et al. (2001) J. Exp. Med. 194:235.
- Fraser, C.C. et al. (2002) Immunogenetics 53:843.
- Munitz, A. et al. (2005) J. Immunol. 174:110.
- Valdez, P.A. et al. (2004) J. Biol. Chem. 279:18662.
- Flaig, R.M. et al. (2004) J. Immunol. 172:6524.
- Cao, E. et al. (2006) Immunity 25:559.
- Stark, S. and C. Watzl (2006) Int. Immunol. 18:241.
- Eissmann, P. and C. Watzl (2006) J. Immunol. 177:3170.
- Howie, D. et al. (2005) J. Immunol. 174:5931.
- Kumar, K.R. et al. (2006) Science 312:1665.
Product Datasheets
Citations for Human NTB-A/SLAMF6 APC-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Species-specific host factors rather than virus-intrinsic virulence determine primate lentiviral pathogenicity
Authors: S Joas, EH Parrish, CW Gnanadurai, E Lump, CM Stürzel, NF Parrish, GH Learn, U Sauermann, B Neumann, KM Rensing, D Fuchs, JM Billingsle, SE Bosinger, G Silvestri, C Apetrei, N Huot, T Garcia-Tel, M Müller-Tru, D Hotter, D Sauter, C Stahl-Henn, BH Hahn, F Kirchhoff
Nat Commun, 2018-04-10;9(1):1371.
-
Human-Specific Adaptations in Vpu Conferring Anti-tetherin Activity Are Critical for Efficient Early HIV-1 Replication In�Vivo
Authors: E Yamada, S Nakaoka, L Klein, E Reith, S Langer, K Hopfensper, S Iwami, G Schreiber, F Kirchhoff, Y Koyanagi, D Sauter, K Sato
Cell Host Microbe, 2018-01-10;23(1):110-120.e7.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance
MBio, 2016-08-16;7(4):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human NTB-A/SLAMF6 APC-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human NTB-A/SLAMF6 APC-conjugated Antibody and earn rewards!
Have you used Human NTB-A/SLAMF6 APC-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
